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ORIGINAL ARTICLE
Bronchodilation in infants with malacia or recurrent
wheeze
W Hofhuis, E C van der Wiel, H A W M Tiddens, G Brinkhorst, W P J Holland,
J C de Jongste, P J F M Merkus
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Background: Controversy remains regarding the effectiveness of bronchodilators in wheezy infants.
Aims: To assess the effect of inhaled β2 agonists on lung function in infants with malacia or recurrent
wheeze, and to determine whether a negative effect of β2 agonists on forced expiratory flow (V′maxFRC)
is more pronounced in infants with airway malacia, compared to infants with wheeze.
Methods: We retrospectively analysed lung function data of 27 infants: eight with malacia, 19 with
recurrent wheeze. Mean (SD) age was 51 (18) weeks. Mean V′maxFRC (in Z score) was assessed before
and after inhalation of β2 agonists.
Results: Baseline V′maxFRC was below reference values for both groups. Following inhalation of β2 ago-
nists the mean (95% CI) change in mean V′maxFRC in Z scores was −0.10 (−0.26 to 0.05) and −0.33
(−0.55 to −0.11) for the malacia and wheeze group, respectively.
Conclusions: In infants with wheeze, inhaled β2 agonists caused a significant reduction in mean V′max-
FRC. Infants with malacia were not more likely to worsen after β2 agonists than were infants with recur-
rent wheeze.
Bronchodilators are widely used for wheezy infants,despite conflicting data on their effectiveness. There arestudies showing a beneficial effect of β2 agonist treatment
in wheezy infants,1–3 studies showing no effect,4–7 and studies
showing an adverse effect.8–10 It seems plausible that contra-
dicting findings are a result of differences in lung function
methodology, mode of aerosol administration, or aetiology of
airway obstruction.
Airway malacia is a condition in which the airway is
unusually collapsible, as a result of a weakness or deficiency of
the cartilaginous elements of the airway wall, or from
decreased tone of themyoelastic elements.11 It has been shown
that reduction of smooth muscle tone makes the airway more
compliant,12 and therefore more collapsible.13 In infants with
intrathoracic tracheomalacia there is limited evidence to sug-
gest that β2 agonists cause deterioration in airway patency.10
Therefore,we hypothesised that a negative effect of β2 agonists
on airway calibre would be more likely and more severe in
infants with airwaymalacia. The study aims were to assess the
nature and magnitude of the bronchodilator response in
infants with malacia or wheeze, and to determine whether a
negative effect of β2 agonists on forced expiratory flows is
more pronounced in the infants with airway malacia.
MATERIALS AND METHODS
Subjects
We retrospectively analysed lung function data of infants with
malacia or recurrent wheeze, who underwent infant lung
function testing (ILFT) before and after the administration of
a β2 agonist. Measurements were performed as part of our
clinical routine between 1998 and 2000 at the outpatient clinic
for paediatric respiratory medicine of the Sophia Children’s
Hospital. The study population consisted of 27 infants (19
boys); eight infants had airway malacia, and 19 infants had
aspecific recurrent wheeze. Aspecific recurrent wheeze was
defined as dyspnoea with wheeze and/or coughing for at least
three episodes of at least seven days, or chronic dyspnoea with
wheeze and/or coughing for at least two months. Infants were
suspected to have airway malacia if they had chronic lower
airway symptoms since the first weeks of life, not responding
to any antiasthma therapy. In all infants with suspected
airway malacia, the diagnosis was confirmed by bronchoscopy
after ILFT. Bronchoscopy was performed by a paediatric
pulmonologist who was unaware of the ILFT data. Airway
malacia was defined as a general or localised weakness of the
trachea or bronchi, resulting in excessive narrowing of the
tracheal or bronchial lumen during expiration or whenever
intrathoracic pressure increases.14 Exclusion criteria were
other illnesses possibly accounting for the dyspnoea, such as
preterm birth, cystic fibrosis, or hernia diaphragmatica. For
ethical reasons bronchoscopy was not performed in the
wheeze group. None of the infants had received broncho-
dilator treatment 12 hours prior to the test.
Methods
Lung function measurements were performed when the
infants were free from acute respiratory symptoms. To prevent
the infants from waking up during the measurements, they
were sedated with chloral hydrate (50–75 mg/kg). Functional
residual capacity (FRCp) was measured by means of a
modified whole body plethysmograph (Jaeger, Würzburg,
Germany). Equipment and procedures were in accordance
with guidelines, in which the FRCp measurement is described
in detail.15 Mean FRCp of 3–5 technically acceptable measure-
ments was expressed as Z score.15 Forced expiratory flow at
FRC (V′maxFRC), used as a measure of airway patency, was
assessed using the end tidal rapid thoracoabdominal compres-
sion (RTC) technique (custom made equipment, Department
for Experimental Medical Instrumentation, Erasmus Univer-
sity Medical Centre, Rotterdam, Netherlands). In short, an
inflatable jacket was wrapped around the infant’s chest and
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abdomen with the arms outside the jacket. At end tidal inspi-
ration the jacket was inflated rapidly, resulting in a forced
partial expiratory flow-volume curve. The flow at FRC was
measured (fig 1). Equipment and procedures were in accord-
ance with guidelines, in which the RTC technique is described
in detail.16 Mean V′maxFRC of 3–5 technically acceptable
measurements was expressed as Z score.16
Study design
After baseline lung function measurements, a β2 agonist was
administered by metered dose inhaler (MDI) per spacer
(Nebuhaler using terbutaline, and Babyhaler using salbuta-
mol). Spacer and canister were shaken for at least five seconds.
One actuation from a salbutamol or terbutaline MDI was
given at a time, while holding the spacer in a horizontal posi-
tion. Next, the spacer was attached vertically to the optimal
fitting facemask used for ILFT. After 10 breaths (counted by 10
opening movements of the inspiration valve of the spacer) the
spacer was removed. Lung function measurements were
repeated after 10 minutes, using the same jacket pressure as
used before bronchodilation. Measurements of FRCp after
bronchodilation could not always be repeated as some
children awoke after the post-bronchodilation V′maxFRC meas-
urements. Heart rate (HR) and transcutaneous oxygen
saturation (SaO2) were monitored continuously by a pulse
oximeter (Nellcor, Hayward, CA, USA).
Analysis
The effect of bronchodilation on ILFT for each infant was
evaluated using a two tailed paired Student’s t test. Subgroups
were compared using the unpaired t test. Correlation
coefficients between baseline and β2 agonist responses were
obtained from linear regression analyses. The significance
level was set at p < 0.05.
RESULTS
Table 1 shows anthropometric data of the 27 infants. Table 2
shows the results of β2 agonist administration on V′maxFRC of the
different groups. Baseline V′maxFRC was below reference values
both groups (table 2). Baseline V′maxFRC in the malacia group
was lower than in wheeze (p = 0.01). Administration of β2
agonist resulted in a reduction of the mean V′maxFRC in both
groups, but this reduction was only significant in the wheeze
group (fig 2). Expressed in Z scores, themean (95% CI) change
was −0.10 (−0.26 to 0.05) for the malacia group, and −0.33
(−0.55 to −0.11) for the wheeze group (p = 0.006). When the
reduction of V′maxFRC was expressed as percentage of baseline, a
similar pattern was observed. For the entire group, mean (SD)
coefficient of variation (CV) was 13.1% (7.25%). When a
significant change in V′maxFRC was defined as being greater than
twice the CV of the baseline measurement,4 only six of 19
infants in the wheeze group had a significant change in
V′maxFRC. Mean V′maxFRC increased in six of 27 infants after β2
agonist administration (three with malacia, and three with
wheeze). The mean (range) FRCp in Z score at baseline for the
total group (n = 27) was −0.20 (−1.66 to 0.54). As a result of
waking up after the post-bronchodilator V′maxFRC measure-
ments, FRCp measurements before and after bronchodilation
could only be obtained in 12 infants (four malacia, eight
wheeze). For these 12 infants the mean (95% CI) change in
FRCp in Z score after bronchodilation was −0.12 (−0.15 to 0.39)
(p = 0.35).
Figure 1 (A) An example of a flow-volume loop from an infant with
recurrent wheeze. (B) An example of a flow-volume loop from an
infant with airway malacia. Note that flow during forced expiration
is similar to flow during tidal expiration.
Table 1 Anthropometric data
Diagnosis
Gender
(M/F) Age (weeks) Weight (kg) Length (cm)
Malacia 5/3
Mean (range) 48 (25–77) 8.2 (6.0–11.1) 72.0 (64.0–82.0)
SD 21 1.6 6.7
Wheeze 14/5
Mean (range) 52 (23–93) 9.5 (7.7–11.3) 75.7 (66.0–82.0)
SD 17 1.1 4.9
Total 19/8
Mean (range) 51 (23–93) 9.1 (6.0–11.3) 74.6 (63.5–82.0)
SD 18 1.4 5.6
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Because of the retrospective nature of this study, β2 agonist
dosage was not standardised. Mean dosage of terbutaline
(n = 24) was 333 µg (range 250–750 µg); mean dosage of
salbutamol (n = 3: malacia = 1, wheeze = 2) was 666 µg
(range 600–800 µg). There was no correlation between β2 ago-
nist dosage and the difference in V′maxFRC as a percentage from
baseline. Heart rate increased significantly after bronchodila-
tion (mean increase (95% CI): 10 (6 to 14) beats/min), used as
an indicator that an adequate dose was delivered into the
lungs. Oxygen saturation did not change significantly after
bronchodilation.
DISCUSSION
We observed a reduction in mean V′maxFRC after β2 agonist
administration in infants with wheeze and malacia. In the
wheeze group this reduction was significant. Worsening of
V′maxFRC following β2 agonists was not more likely to occur in
infants with malacia than in infants with wheeze. Therefore,
we reject the hypothesis that a negative effect of β2 agonist
administration on V′maxFRC is more pronounced in infants with
airway malacia, compared to infants with wheeze.
A possible explanation for our finding could be that baseline
V′maxFRC was significantly lower in themalacia group,with flows
sometimes limited to (near) tidal levels (fig 1B), and thus
leaving little room for further deteriorations. Conversely, at
these levels a small deterioration in lung function may be
clinically more significant than a larger deterioration at higher
lung function, as was seen in the wheeze group. Another
explanation could be that, in malacia, forced expiration
assessed with the RTC technique is affected by dynamic com-
pression to such an extent that a further reduction of smooth
muscle tone by bronchodilation does not result in further
deterioration of airway patency. Furthermore, a decrease in
FRC after bronchodilation could have masked a broncho-
dilator response, since airway resistance is higher at lower
lung volumes.17 We think this is unlikely, as we could not show
a change in mean FRCp after bronchodilation.
The significant reduction in mean V′maxFRC in the wheeze
group could be explained by the fact that the majority of
infants (about 60%) with wheezing do not necessarily have
reversible bronchoconstriction, but transient conditions asso-
ciated with diminished airway patency.18 A reduction of
smooth muscle tone by bronchodilation could make the
airways more compliant, and therefore more collapsible,
resulting in increased dynamic compression and reduced
forced expiratory flows.12 13 Another possible explanation for
the significant reduction in mean V′maxFRC is that the wheeze
group was studied while asymptomatic when scope for
improvement may be limited and scope for deterioration
greater. The significant reduction in mean V′maxFRC in the
wheeze group cannot be explained by a difference in β2 agonist
dosage since the mean dose was not different between groups.
One could argue whether the mean decrease in V′maxFRC in the
wheeze group is clinically relevant, because when a significant
change in V′maxFRC was defined as greater than twice the CV of
the baseline measurement,4 no significant changes in V′maxFRC
in either group were seen. The lack of a change in V′maxFRC after
bronchodilators in wheezy infants has also been observed
previously.4 5 A possible explanation could be that, according
to recommendations, V′maxFRC after bronchodilation is assessed
with the same jacket pressure as used before the
administration.16 Possibly, one should assess the lowest
pressure at which the highest flows are obtained both before
and after β2 agonist administration.
Modl and co-workers17 showed a positive effect of β2 agonist
administration on mean V′maxFRC by means of the raised volume
rapid thoracoabdominal compression (RVRTC) technique,
suggesting that the RVRTC techniquemight be a better test for
assessing forced expiratory flow. Assessing airway patency by
means of the RVRTC technique is promising but has not yet
proved to be beneficial over the RTC technique.19 Furthermore,
RVRTC technique is not standardised since it lacks
consensus.16 20 Although the RTC technique is well accepted
and standardised, several disadvantages have become appar-
ent. First, measurement of V′maxFRC relies on FRC not changing
between forced expirations. There is abundant evidence that
FRC is not stable and shifts with dynamic events such as
changes in airway calibre (bronchodilation) or sleep state.21
This explains the high variability of V′maxFRC for which
coefficients of variation range from 11% to 36%.21 Second, flow
limitation is difficult to ascertain, especially in healthy infants.
Finally, RTC technique assesses airway function in the tidal
volume range only, which reduces its sensitivity.20 21
This study suggests that, in clinically stable infants, mean
forced expiratory flows by means of the RTC technique do not









Z score (95% CI)
Pre β2 agonist Post β2 agonist Post β2 agonist Pre β2 agonist Post β2 agonist Post β2 agonist
Malacia
(n=8) 56.2 (17 to 89) 47.5 (32 to 91) −6.3 (−40.7 to 28.0) −2.64 (−3.58 to −1.41) −2.75 (−3.74 to −1.38) −0.10 (−0.26 to 0.05)
Wheeze
(n=19) 167.1 (32 to 420) 139.8 (32 to 344) −13.1 (−25.1 to −1.1) −1.50 (−3.94 to 1.72) −1.83 (−4.02 to 0.44) −0.33 (−0.55 to −0.11)
Figure 2 Individual responses of V′maxFRC before and after β2 agonist
administration. Output organised by groups. Separate dots are
mean group values with SEM.
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improve following inhaled bronchodilators. On the contrary, β2
agonist administrationmay produce an increase inmeanwork
of breathing per minute,22 oxygen consumption, and minute
ventilation, possibly as the result of an increase of metabolic
rate.23 Thus, β2 agonists may not always be beneficial in infants
with airway obstruction.
We conclude that mean V′maxFRC is reduced and did not
improve after inhalation of β2 agonists in infants with malacia
or wheeze. In infants with wheeze there was a significant
reduction in mean V′maxFRC after inhalation of β2 agonists. Chil-
dren with malacia were not more likely to worsen after β2 ago-
nists. We recommend that the response to inhaled β2 agonists
in infants with airway obstruction should always be critically
evaluated.
ACKNOWLEDGEMENT
This study was supported by an unrestricted grant from GlaxoSmith-
Kline, Netherlands.
. . . . . . . . . . . . . . . . . . . . .
Authors’ affiliations
W Hofhuis, E C van der Wiel, H A W M Tiddens, J C de Jongste,
P J F M Merkus, Department of Paediatrics, Division of Respiratory
Medicine, Erasmus University Medical Centre, Sophia Children’s
Hospital, Rotterdam, Netherlands
G Brinkhorst, Department of Paediatrics, Medical Centre Alkmaar,
Alkmaar, Netherlands
W P J Holland, Department for Experimental Medical Instrumentation,
Erasmus University Medical Centre, Rotterdam, Netherlands
REFERENCES
1 Kraemer R, Frey U, Sommer CW, et al. Short-term effect of albuterol,
delivered via a new auxiliary device, in wheezy infants. Am Rev Respir
Dis 1991;144:347–51.
2 Alario AJ, Lewander WJ, Dennehy P, et al. The efficacy of nebulized
metaproterenol in wheezing infants and young children. Am J Dis Child
1992;146:412–18.
3 Bentur L, Canny GJ, Shields MD, et al. Controlled trial of nebulized
albuterol in children younger than 2 years of age with acute asthma.
Pediatrics 1992;89:133–7.
4 Sly PD, Lanteri CJ, Raven JM. Do wheezy infants recovering from
bronchiolitis respond to inhaled salbutamol? Pediatr Pulmonol
1991;10:36–9.
5 Clarke JR, Aston H, Silverman M. Delivery of salbutamol by metered
dose inhaler and valved spacer to wheezy infants: effect on bronchial
responsiveness. Arch Dis Child 1993;69:125–9.
6 Hayden MJ, Wildhaber JH, LeSouef PN. Bronchodilator responsiveness
testing using raised volume forced expiration in recurrently wheezing
infants. Pediatr Pulmonol 1998;26:35–41.
7 Chavasse RJ, Bastian-Lee Y, Richter H, et al. Inhaled salbutamol for
wheezy infants: a randomised controlled trial. Arch Dis Child
2000;82:370–5.
8 O’Callaghan C, Milner AD, Swarbrick A. Paradoxical deterioration in
lung function after nebulised salbutamol in wheezy infants. Lancet
1986;2:1424–5.
9 Prendiville A, Green S, Silverman M. Paradoxical response to nebulised
salbutamol in wheezy infants, assessed by partial expiratory flow-volume
curves. Thorax 1987;42:86–91.
10 Panitch HB, Keklikian EN, Motley RA, et al. Effect of altering smooth
muscle tone on maximal expiratory flows in patients with tracheomalacia.
Pediatr Pulmonol 1990;9:170–6.
11 Baxter J, Dunbar J. Tracheomalacia. Ann Otol Rhinol Laryngol
1963;72:1013–23.
12 Bouhuys A, Van de Woestijne KP. Mechanical consequences of airway
smooth muscle relaxation. J Appl Physiol 1971;30:670–6.
13 Tiddens HA, Hofhuis W, Bogaard JM, et al. Compliance, hysteresis,
and collapsibility of human small airways. Am J Respir Crit Care Med
1999;160:1110–18.
14 Messineo A, Filler RM. Tracheomalacia. Semin Pediatr Surg
1994;3:253–8.
15 Stocks J, Godfrey S, Beardsmore C, et al. Plethysmographic
measurements of lung volume and airway resistance. ERS/ATS Task
Force on Standards for Infant Respiratory Function Testing. European
Respiratory Society/ American Thoracic Society. Eur Respir J
2001;17:302–12.
16 Sly PD, Tepper R, Henschen M, et al. Tidal forced expirations. Eur
Respir J 2000;16:741–8.
17 Modl M, Eber E, Weinhandl E, et al. Assessment of bronchodilator
responsiveness in infants with bronchiolitis. A comparison of the tidal and
the raised volume rapid thoracoabdominal compression technique. Am J
Respir Crit Care Med 2000;161(3 pt 1):763–8.
18 Martinez FD, Wright AL, Taussig LM, et al. Asthma and wheezing in the
first six years of life. The Group Health Medical Associates. N Engl J Med
1995;332133–8.
19 Ranganathan SC, Hoo AF, Lum SY, et al. Exploring the relationship
between forced maximal flow at functional residual capacity and
parameters of forced expiration from raised lung volume in healthy
infants. Pediatr Pulmonol 2002;33:419–28.
20 The Joint American Thoracic Society/European Respiratory Society
Working Group on Infant Lung Function. The raised volume rapid
thoracoabdominal compression technique. Am J Respir Crit Care Med
2000;161:1760–2.
21 Le Souef PN, Castile RG, Turner DJ, et al. Forced expiratory maneuvers.
In: Stocks J, Sly PD, Tepper RS, Morgan WJ, eds. Infant respiratory
function testing. New York: Wiley-Liss, Inc., 1996:379–409.
22 Stokes GM, Milner AD, Hodges IG, et al. Nebulised therapy in acute
severe bronchiolitis in infancy. Arch Dis Child 1983;58:279–82.
23 Newth CJ, Amsler B, Richardson BP, et al. The effects of bronchodilators
on spontaneous ventilation and oxygen consumption in rhesus monkeys.
Pediatr Res 1997;42:157–62.
Bronchodilation in infants with airway obstruction 249
www.archdischild.com
 on 13 November 2006 adc.bmj.comDownloaded from 
